L R Avni-Singer1, A Yakely2, S S Sheth3, E D Shapiro4, L M Niccolai2, C R Oliveira5. 1. Yale School of Public Health, Department of Epidemiology of Microbial Diseases, 60 College Street, New Haven, CT, 06520, USA. Electronic address: lital.avnisinger@gmail.com. 2. Yale School of Public Health, Department of Epidemiology of Microbial Diseases, 60 College Street, New Haven, CT, 06520, USA. 3. Yale School of Medicine, Department of Obstetrics and Gynecology, 333 Cedar Street, PO Box 208063, Suite 302 FMB, New Haven, CT, 06520, USA. 4. Yale School of Public Health, Department of Epidemiology of Microbial Diseases, 60 College Street, New Haven, CT, 06520, USA; Yale School of Medicine, Department of Pediatrics, P.O. Box 208064, New Haven, CT, 06520-8064, USA. 5. Yale School of Medicine, Department of Pediatrics, P.O. Box 208064, New Haven, CT, 06520-8064, USA.
Abstract
OBJECTIVES: Sociodemographic disparities in the incidence and mortality of human papillomavirus (HPV)-associated conditions have been well documented in the pre-HPV vaccine era. It is still unknown if the introduction of routine vaccination has been effective in reducing these prevaccine era inequalities. The purpose of this review was to determine the utilization of sociodemographic variables to assess for disparities in population-level HPV vaccine impact research and to evaluate the current evidence for disparities in the reduction of HPV-associated conditions after vaccine introduction in the United States (US). STUDY DESIGN: A systematic review of the literature from January 2007 through March 2018 was carried out to identify studies evaluating the impact HPV vaccines have had on the rates of HPV infection, genital warts, and cervical dysplasia (cervical intraepithelial neoplasia grades 1+) in the US. An in-depth review was then performed to synthesize these data and to assess the way prior studies have reported and evaluated for potential disparities in the vaccine's impact within various racial, ethnic, and/or socio-economic subgroups of the population. METHODS: Vaccine impact studies measure the change in the population-level burden of disease prelicensure versus postlicensure of the vaccine. We systematically searched PubMed/Medline and Embase, combining search terms related to the HPV vaccine, sentinel surveillance, and HPV-associated conditions. Eligible studies were those with population-level, postvaccine introduction data that were conducted in the US. Finally, a cited reference search was conducted for all included articles using the Web of Science platform that accesses three major citation indexes: Science Citation Index, Social Sciences Citation Index, and Arts and Humanities Citation Index. This allowed us to screen not only the articles that were cited by our final collection of studies but also the articles that used our selected studies as one of their references. The study protocol is registered in PROSPERO (#CRD42018107579). RESULTS: Overall, 23 of the 4139 references retrieved assessed the population-level impact of HPV vaccines between January 1, 2007, and March 29, 2018. Among these, 13 (57%) reported sociodemographic data. Only two articles reported stratified results by sociodemographic factors, thereby allowing assessment for potential disparate impact. One of these studies described differences in the impact of the vaccine by race, ethnicity, and income. CONCLUSION: Although approximately half of the studies that assessed the impact of the HPV vaccine measured sociodemographic characteristics, few presented results in a way that allowed for the identification of potential differences in impact between the relevant subgroups of the population. Determining to what extent, if any, vaccines are reducing known sociodemographic disparities is an important public health priority and an essential step in developing immunization strategies that are beneficial for all.
OBJECTIVES: Sociodemographic disparities in the incidence and mortality of human papillomavirus (HPV)-associated conditions have been well documented in the pre-HPV vaccine era. It is still unknown if the introduction of routine vaccination has been effective in reducing these prevaccine era inequalities. The purpose of this review was to determine the utilization of sociodemographic variables to assess for disparities in population-level HPV vaccine impact research and to evaluate the current evidence for disparities in the reduction of HPV-associated conditions after vaccine introduction in the United States (US). STUDY DESIGN: A systematic review of the literature from January 2007 through March 2018 was carried out to identify studies evaluating the impact HPV vaccines have had on the rates of HPV infection, genital warts, and cervical dysplasia (cervical intraepithelial neoplasia grades 1+) in the US. An in-depth review was then performed to synthesize these data and to assess the way prior studies have reported and evaluated for potential disparities in the vaccine's impact within various racial, ethnic, and/or socio-economic subgroups of the population. METHODS: Vaccine impact studies measure the change in the population-level burden of disease prelicensure versus postlicensure of the vaccine. We systematically searched PubMed/Medline and Embase, combining search terms related to the HPV vaccine, sentinel surveillance, and HPV-associated conditions. Eligible studies were those with population-level, postvaccine introduction data that were conducted in the US. Finally, a cited reference search was conducted for all included articles using the Web of Science platform that accesses three major citation indexes: Science Citation Index, Social Sciences Citation Index, and Arts and Humanities Citation Index. This allowed us to screen not only the articles that were cited by our final collection of studies but also the articles that used our selected studies as one of their references. The study protocol is registered in PROSPERO (#CRD42018107579). RESULTS: Overall, 23 of the 4139 references retrieved assessed the population-level impact of HPV vaccines between January 1, 2007, and March 29, 2018. Among these, 13 (57%) reported sociodemographic data. Only two articles reported stratified results by sociodemographic factors, thereby allowing assessment for potential disparate impact. One of these studies described differences in the impact of the vaccine by race, ethnicity, and income. CONCLUSION: Although approximately half of the studies that assessed the impact of the HPV vaccine measured sociodemographic characteristics, few presented results in a way that allowed for the identification of potential differences in impact between the relevant subgroups of the population. Determining to what extent, if any, vaccines are reducing known sociodemographic disparities is an important public health priority and an essential step in developing immunization strategies that are beneficial for all.
Authors: Lauri E Markowitz; Gui Liu; Susan Hariri; Martin Steinau; Eileen F Dunne; Elizabeth R Unger Journal: Pediatrics Date: 2016-02-22 Impact factor: 7.124
Authors: Eileen F Dunne; Allison Naleway; Ning Smith; Bradley Crane; Sheila Weinmann; Jim Braxton; Martin Steinau; Elizabeth R Unger; Lauri E Markowitz Journal: J Infect Dis Date: 2015-06-29 Impact factor: 5.226
Authors: Susan Hariri; Michelle L Johnson; Nancy M Bennett; Heidi M Bauer; Ina U Park; Sean Schafer; Linda M Niccolai; Elizabeth R Unger; Lauri E Markowitz Journal: Cancer Date: 2015-06-22 Impact factor: 6.860
Authors: Linda M Niccolai; Pamela J Julian; James I Meek; Vanessa McBride; James L Hadler; Lynn E Sosa Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-05-23 Impact factor: 4.254
Authors: Suzanne M Garland; Marc Steben; Heather L Sings; Margaret James; Shuang Lu; Radha Railkar; Eliav Barr; Richard M Haupt; Elmar A Joura Journal: J Infect Dis Date: 2009-03-15 Impact factor: 5.226
Authors: Vicki B Benard; Philip E Castle; Steven A Jenison; William C Hunt; Jane J Kim; Jack Cuzick; Ji-Hyun Lee; Ruofei Du; Michael Robertson; Scott Norville; Cosette M Wheeler Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Monica M Brackney; Daniel M Weinberger; Kyle Higgins; James Meek; Linda M Niccolai Journal: Public Health Rep Date: 2021-11-02 Impact factor: 3.117
Authors: Emilia M Jalil; Erin C Wilson; Laylla Monteiro; Luciane S de Velasque; Ana Cristina G Ferreira; Sandro C Nazer; Ruth K Friedman; Valdilea G Veloso; José Eduardo Levi; Beatriz Grinsztejn Journal: J Int AIDS Soc Date: 2021-03 Impact factor: 5.396